Cassava Sciences (SAVA)
NASDAQ:SAVA

Cassava Sciences Stock Analysis & Ratings

SAVA Stock Chart & Stats

Day’s Range$25.15 - $27.68
52-Week Range$15.72 - $146.16
Previous Close$25.15
Volume1.31M
Average Volume (3M)1.67M
Market Cap$1.09B
P/E Ratio-23.5
Beta0.96
Next EarningsAug 16, 2022
Dividend YieldN/A
Smart Score6
EPS (TTM)-1.16


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

SAVA FAQ

What was Cassava Sciences’s price range in the past 12 months?
Cassava Sciences lowest stock price was $15.72 and its highest was $146.16 in the past 12 months.
    What is Cassava Sciences’s market cap?
    Cassava Sciences’s market cap is $1.09B.
      What is Cassava Sciences’s price target?
      The average price target for Cassava Sciences is $63.33. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $124.00 ,the lowest forecast is $8.00. The average price target represents 132.57% Increase from the current price of $27.23.
        What do analysts say about Cassava Sciences?
        Cassava Sciences’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Cassava Sciences’s upcoming earnings report date?
          Cassava Sciences’s upcoming earnings report date is Aug 16, 2022 which is in 84 days.
            How were Cassava Sciences’s earnings last quarter?
            Cassava Sciences released its earnings results on May 05, 2022. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.025.
              Is Cassava Sciences overvalued?
              According to Wall Street analysts Cassava Sciences’s price is currently Undervalued.
                Does Cassava Sciences pay dividends?
                Cassava Sciences pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. Cassava Sciences’s last Notavailable dividend payment was on Dec 24, 2012. Cassava Sciences’s upcoming ex-dividend date is Dec 13, 2012
                  What is Cassava Sciences’s EPS estimate?
                  Cassava Sciences’s EPS estimate for its next earnings report is not yet available.
                  How many shares outstanding does Cassava Sciences have?
                  Cassava Sciences has 40,080,000 shares outstanding.
                    What happened to Cassava Sciences’s price movement after its last earnings report?
                    Cassava Sciences reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went down -1.705%.
                      Which hedge fund is a major shareholder of Cassava Sciences?
                      Among the largest hedge funds holding Cassava Sciences’s share is Greenlight Capital Inc. It holds Cassava Sciences’s shares valued at N/A.

                        ---

                        Cassava Sciences Stock Analysis

                        The Cassava Sciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Cassava Sciences

                        Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

                        ---
                        Similar Stocks
                        Company
                        Price & Change
                        Follow
                        Collegium Pharmaceutical
                        Acura Pharmaceuticals
                        KemPharm
                        Johnson & Johnson
                        Durect

                        Popular Stocks

                        ---
                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis